MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

44.28 -1.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

43.21

Max

44.91

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+22.62% upside

Turustatistika
By TradingEconomics
Turukapital	196M 3.4B
Eelmine avamishind	45.48
Eelmine sulgemishind	44.28

Uudiste sentiment

By Acuity

25%

75%

40 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. jaan 2026, 21:07 UTC

Tulu

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2. jaan 2026, 20:09 UTC

Market Talk

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2. jaan 2026, 19:48 UTC

Market Talk

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2. jaan 2026, 18:53 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. jaan 2026, 18:53 UTC

Market Talk

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2. jaan 2026, 17:56 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2. jaan 2026, 17:50 UTC

Market Talk

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2. jaan 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. jaan 2026, 16:33 UTC

Market Talk

Remittances to Mexico Fell 5.7% in November -- Market Talk

2. jaan 2026, 16:18 UTC

Market Talk

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2. jaan 2026, 15:48 UTC

Tulu

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2. jaan 2026, 15:17 UTC

Market Talk

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2. jaan 2026, 15:01 UTC

Market Talk

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2. jaan 2026, 15:00 UTC

Tulu

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2. jaan 2026, 14:56 UTC

Market Talk

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2. jaan 2026, 14:20 UTC

Market Talk

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2. jaan 2026, 14:20 UTC

Market Talk

Global Equities Roundup: Market Talk

2. jaan 2026, 14:13 UTC

Market Talk

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2. jaan 2026, 13:39 UTC

Market Talk

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2. jaan 2026, 13:01 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2. jaan 2026, 12:45 UTC

Market Talk

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2. jaan 2026, 11:48 UTC

Market Talk

European Gas Climbs as Cold Weather Bites -- Market Talk

2. jaan 2026, 11:36 UTC

Market Talk

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2. jaan 2026, 11:30 UTC

Market Talk

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2. jaan 2026, 11:29 UTC

Market Talk

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2. jaan 2026, 11:15 UTC

Market Talk

Global Energy Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

22.62% tõus

12 kuu keskmine prognoos

Keskmine 54.96 USD 22.62%

Kõrge 65 USD

Madal 44 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

Osta

Hoia

Müü

Põhineb 15 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

40 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.